OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update
Major expansion of clinical portfolio including initiation of clinical trials with Tedopi® in ovarian cancer,
Major expansion of clinical portfolio including initiation of clinical trials with Tedopi® in ovarian cancer,